论文部分内容阅读
目的:检测乳腺浸润性导管癌组织中CD147、MMP-9及AnnexinⅡ蛋白的表达。方法:应用免疫组织化学SP法检测60例乳腺浸润性导管癌组织及60例乳腺纤维腺瘤组织中CD147、MMP-9和AnnexinⅡ蛋白的表达,并分析3者与乳腺浸润性导管癌临床病理特征的关系。结果:乳腺浸润性导管癌组织中CD147、MMP-9和AnnexinⅡ蛋白的阳性表达率分别是91.7%、86.7%及90.0%,明显高于各自在乳腺纤维腺瘤组织中的表达率(6.7%、6.7%及3.3%,P<0.001);伴有淋巴结转移的浸润性导管癌组织中CD147、MMP-9和AnnexinⅡ蛋白的表达率明显高于无淋巴结转移组(P<0.05);组织学分级越高,以上3种蛋白的表达率越高(P<0.05)。结论:CD147、MMP-9和AnnexinⅡ蛋白的异常高表达可能促进了乳腺浸润性导管癌的发展。
Objective: To detect the expression of CD147, MMP-9 and AnnexinⅡin breast invasive ductal carcinoma. Methods: The expressions of CD147, MMP-9 and Annexin Ⅱ in 60 cases of invasive ductal carcinoma of breast and 60 cases of breast fibroadenoma were detected by immunohistochemical SP method. The clinicopathological features of 3 and breast invasive ductal carcinoma Relationship. Results: The positive rates of CD147, MMP-9 and AnnexinⅡ in breast invasive ductal carcinoma were 91.7%, 86.7% and 90.0%, respectively, which were significantly higher than those in breast fibroadenoma (6.7% 6.7%, and 3.3% respectively) (P <0.001). The expressions of CD147, MMP-9 and AnnexinⅡ in invasive ductal carcinomas with lymph node metastasis were significantly higher than those without lymph node metastasis (P <0.05) High, the above three kinds of protein expression rate is higher (P <0.05). Conclusion: The abnormally high expression of CD147, MMP-9 and AnnexinⅡ may promote the development of invasive ductal carcinoma of the breast.